

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
29 September 2005 (29.09.2005)

PCT

(10) International Publication Number  
**WO 2005/089728 A2**

- (51) International Patent Classification<sup>7</sup>: **A61K 9/70**, 31/465
- (21) International Application Number: PCT/IB2005/000673
- (22) International Filing Date: 10 March 2005 (10.03.2005)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
0400685-4 19 March 2004 (19.03.2004) SE  
60/558,874 2 April 2004 (02.04.2004) US
- (71) Applicant (for all designated States except US): **PFIZER HEALTH AB** [SE/SE]; S-112 87 Stockholm (SE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **LINDELL, Eva**, Anette, Katarina [SE/SE]; Pfizer Health AB, Norrbroplatsen 2, S-251 09, Helsingborg (SE). **NICKLASSON, Per, Fredrik** [SE/SE]; Pfizer Health AB, Norrbroplatsen 2, S-251 09, Helsingborg (SE). **THYRESSON, Maarit, Kristina** [FI/SE]; Pfizer Health AB, Norrbroplatsen 2, S-251 09, Helsingborg (SE).
- (74) Agents: **WOOD, David, J.** et al.; Pfizer Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— without international search report and to be republished upon receipt of that report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



**WO 2005/089728 A2**

(54) Title: MEANS FOR TRANSDERMAL ADMINISTRATION OF NICOTINE

(57) Abstract: Devices for transdermal administration of nicotine, which provide for basic as well as additional user activatable administration of nicotine, as well as use of such devices.

**BEST AVAILABLE COPY**

## MEANS FOR TRANSDERMAL ADMINISTRATION OF NICOTINE

### Technical Field

The present invention relates to devices for transdermal administration of nicotine,  
5 specifically such devices providing for basic as well as additional user activatable administration of nicotine. The present invention also relates to use of said devices.

### Background of the Invention

#### *Tobacco dependence and reduction thereof*

In recent years, with the recognition of the harmful effects of tobacco smoking,  
10 there have been numerous campaigns and programs by governmental agencies and various health groups and other interested organisations to disseminate information about the adverse health effects resulting from tobacco smoking. Moreover, and as a result of this recognition of the harmful effects, there have been many programs directed to attempts in reducing smoking incidence.

15 Nicotine is an organic compound and is the principal alkaloid of tobacco. Nicotine is the chief addictive ingredient in the tobacco used in cigarettes, cigars, snuff and the like. Nicotine is also an addictive drug, though, and smokers characteristically display a strong tendency to relapse after having successfully stopped smoking for a time. Nicotine is the worlds second most used drug, after caffeine from coffee and tea.

20 The main problem with tobacco smoking is its enormous implications on health. It is estimated that smoking related diseases cause some 3 – 4 million deaths per year globally. According to Centers for Disease Control and Prevention. Cigarette smoking among adults – United States, 1995. MMWR 1997;46:1217 – 1220 around 500,000 persons in USA die each year as a result of tobacco use. In fact, excessive smoking is now  
25 recognised as one of the major health problems throughout the world. This grim consequence of tobacco smoking has urged many medical associations and health authorities to take very strong actions against the use of tobacco.

Even though tobacco smoking is decreasing in many developed countries today it is hard to see how the societies could get rid of the world's second most used drug.

30 The most advantageous thing a heavy smoker can do is to reduce or preferably even stop smoking completely. Experience shows, however, that most smokers find this extremely difficult since, mostly, tobacco smoking results in a dependence disorder or craving. The WHO has in its International Classification of Disorders a diagnosis called

Tobacco Dependence. Others like the American Psychiatric Association call the addiction Nicotine Dependence. It is generally accepted that these difficulties to stop smoking result from the fact those heavy smokers are dependent on nicotine. The most important risk factors are, however, substances that are formed during the combustion of tobacco, such as  
5 carbon monoxide, tar products, aldehydes, and hydro cyanic acid.

#### *Effects of nicotine*

The administration of nicotine can give satisfaction and the usual method is by smoking, either by smoking e g a cigarette, a cigar or a pipe. However, smoking has health hazards and it is therefore desirable to formulate an alternative way of administering nico-  
10 tine in a pleasurable manner that can be used to facilitate withdrawal from smoking and/or used as a replacement for smoking.

When smoking a cigarette, nicotine is quickly absorbed into the smoker's blood and reaches the brain within around ten seconds after inhalation. The quick uptake of nicotine gives the consumer a rapid satisfaction, or kick. The satisfaction, then, lasts during the  
15 smoking time of the cigarette and for a period of time thereafter. The poisonous, toxic, carcinogenic, and addictive nature of smoking has provided efforts for methods, compositions and devices, which help in breaking the habit of smoking cigarettes.

Nicotine is an addictive poisonous alkaloid  $C_5H_4NC_4H_7NCH_3$ , derived from the tobacco plant. Nicotine is also used as an insecticide.

#### 20 *Nicotine replacement products*

One way to reduce smoking is to provide nicotine in a form or manner other than by smoking and some products have been developed to fulfil this need. Nicotine containing formulations are currently the dominating treatments for tobacco dependence.

The successes in achieving reduction in the incidence of smoking have been rela-  
25 tively poor using presently known products. The present state of the art involves both behavioural approaches and pharmacological approaches. More than 80 % of the tobacco smokers who initially quit smoking after using some behavioural or pharmacological approach to singly reduce smoking incidence generally relapse and return to the habit of smoking at their former rate of smoking within about a one year's period of time.

30 As an aid for those who are willing to stop smoking there are several ways and forms of nicotine replacement products available on the market, such as nicotine chewing gum. Several methods and means have been described for diminishing the desire of a subject to use tobacco, which comprises the step of administering to the subject nicotine or

a derivative thereof as described in e g US 5,810,018 (oral nicotine spray), US 5,939,100 (nicotine containing microspheres) and US 4,967,773 (nicotine containing lozenge).

Nicotine-containing nose drops have been reported (Russell et al., British Medical Journal, Vol. 286, p. 683 (1983); Jarvis et al., Brit. J. of Addiction, Vol. 82, p. 983 (1987)).

5 Nose drops, however, are difficult to administer and are not convenient for use at work or in other public situations. Ways of administering nicotine by way of delivering directly into the nasal cavity by spraying is known from US 4,579,858, DE 32 41 437 and WO93/127 64. There may, though, be local nasal irritation with use of nasal nicotine formulations. The difficulty in administration also results in unpredictability of the dose of  
10 nicotine administered.

Also, inhaling devices resembling a cigarette are known for uptake of nicotine vapours as suggested in US 5,167,242.

One successful approach to date in reducing the incidence of smoking relies upon nicotine containing chewing gum that is designed to reduce smoking withdrawal  
15 symptoms. The reported success rate is approximately twice that of placebo.

One successful product that is used as a smoking substitute and/or as a smoking cessation aid and which is based on nicotine, is the chewing gum Nicorette®. This product was one of the first nicotine replacement forms that was approved by the Food and Drug Administration (FDA) and is still one of the most used nicotine replacement products.  
20 Nicorette® chewing gum has been on the market in about 60 countries for several years. In this chewing gum the nicotine is present in the form of a complex with an insoluble cation-exchanger (polacrilex) that is dispersed in a gum base. The nicotine is slowly released from the gum due to chewing and will reach similar plasma levels as when smoking a cigarette after about 30 minutes depending on the chewing technique, i e slow or active chewing.  
25 Patents related to this product are e g US Patents 3,877,468, 3,901,248 and 3,845,217.

#### *Nicotine transdermal patches*

The use of skin patches for transdermal administration of nicotine was reported many years ago (Rose, in Pharmacologic Treatment of Tobacco Dependence, (1986) pp. 158-166, Harvard Univ. Press). A large number of patents on devices for transdermal  
30 delivery of nicotine have been issued, e g US 5,120,546 disclosing a transdermal delivery system wherein the nicotine is complexed to a cyclo compound, US 5,230,896 disclosing a transdermal delivery system wherein is made use of an acrylic polymer adhesive, US 4,943,435 disclosing a transdermal patch for delivering nicotine for 12 – 24 hours making

use of a rate-controlling membrane, US 4,915,950 disclosing a method for making nicotine-containing transdermal delivery devices whereby the nicotine is printed onto an adsorbent fabric layer, US 5,533,995 disclosing a transdermal device wherein the nicotine transport within the device as such is controllable using an internal electrode system, US 5,135,753 disclosing a transdermal device for administering nicotine combined with a nicotine-containing lozenge, US 5,721,257 disclosing a transdermal device for administering nicotine combined with a nasal spray for administering nicotine, WO 0164149 disclosing use of a device for transdermally administering nicotine in combination with heat, and WO 9600111 disclosing transdermal delivery of a drug, e g nicotine, using electrical pulses.

*Prior art and problems thereof*

There are known methods for providing an essentially constant base-line plasma level of nicotine being supplemented with boost doses of nicotine when the patient so desires. These methods to date imply use of two different dosage forms for delivery of nicotine to be used in combination. For this purpose may e g be used a nicotine patch in combination with a nicotine lozenge, see US 5,135,753, or a nicotine patch in combination with a nicotine nasal spray, see US 5,721,257. For convenience of the user there is a need to provide a single dosage form, which may provide an essentially constant base-line plasma level of nicotine as well as additional boost doses of nicotine when the patient/user so desires.

The present invention pertains to a solution to the captioned problem by providing a unitary device, which accounts for a basic as well as an additional user activatable transdermal delivery of nicotine.

It is highly desirable in light of the aforementioned problems to develop means and methods for the administration of nicotine to provide satisfaction to a person craving for nicotine or to provide a sense of smoking satisfaction without smoking, which can also avoid problems associated with the prior art means and methods. In this respect, the present invention addresses this need and interest.

**Definitions**

With "basic transdermal administration of nicotine in any form " and similar expressions is herein meant transdermal nicotine transport provided by a part of the claimed device that administers nicotine continuously during the period of the intended application of the claimed device on the skin.

With "additional transdermal administration of nicotine in any form " and similar expressions is herein meant transdermal nicotine transport provided by a part of the claimed device that at user activation administers additional nicotine, beyond that provided by the part of the claimed device providing for basic administration of nicotine in any form.

5

#### **Legend of Figures**

Figure 1 is a schematic drawing of the embodiment according to Example 1.

Figure 2 is a schematic drawing of the embodiment according to Example 2.

Figure 3 is a schematic drawing of the embodiment according to Example 3.

10 Figure 4 is a schematic drawing of the embodiment according to Example 4.

Figure 5 is a schematic drawing of the embodiment according to Example 5.

Figure 6 is a schematic drawing of the embodiment according to Example 6.

#### **Summary of the Invention**

15 In view of the foregoing disadvantages known in the art when trying to deliver nicotine to a subject to provide different delivery rates of nicotine to a subject the present invention provides novel devices for combined basic and additional user activatable transdermal delivery of nicotine.

Further, the present invention provides use of nicotine for the manufacture of a device, and a method for aiding in smoking cessation, in temporary smoking abstinence  
20 and/or in reducing the urge to smoke or to otherwise use tobacco containing material, and/or for treating conditions suitable for treatment with nicotine, such conditions being selected from the group consisting of Alzheimer's disease, Crohn's disease, Parkinson's disease, Tourette's syndrome, ulcerous colitis and post-smoking-cessation weight control by transdermal administration of nicotine with such a device. The method of transdermal  
25 delivery of nicotine can also be practiced in combination with means for delivering of nicotine selected from mouth sprays, nasal sprays, transdermal patches, inhaling devices, lozenges, tablets and from parenteral methods, subcutaneous methods, intravenous methods, rectal methods, vaginal methods and transmucoasal methods, including use of tobacco.

#### **30 Categorization of transdermal devices**

Means for transdermal administration of nicotine in any form can be categorized in many different ways. A comprehensive categorization of transdermal devices useful in the present invention is in four main groups as follows:

- the reservoir type, in which the drug is placed in a liquid or a gel and delivered across a rate-moderating membrane to the skin;

- the matrix type, in which the drug is placed within a non-adhesive polymeric material, typically a hydrogel or soft polymer;

- 5       - the drug-in-adhesive type, in which the drug is placed within an adhesive polymer;
- the multi-laminate type, which is similar to the drug-in-adhesive design, but which incorporates an additional layer of pressure sensitive adhesive to cover the entire device and affix it to the skin. A membrane can also be incorporated into the multi-laminate type.

#### User activatable delivery of nicotine

- 10       Means for modifying transdermal flux of pharmaceutically active substances can be categorized in many different ways. One such categorization is according to below Table 2.

      Since many of the means listed in Table 2 may be designed to be both activated and deactivated by the user, they may be well suited to be used for additional transdermal administration of nicotine in the present invention. Means especially suited for user activation  
15 and deactivation, and thus preferred for use in additional transdermal administration of nicotine of the present invention include, but are not limited to: iontophoresis (including also electromigration and electroosmosis), sonophoresis, micro-needles, jet injection or combinations thereof.

**Table 2. Means for modifying transdermal delivery**

20

Means	Mechanism
Iontophoresis (electromigration, electroosmosis)	Transport of charged drug molecules in an electrical field drives drug molecules through the Stratum Corneum (SC), enhancing transdermal transport rate.
Electroporation	Transport-enhancing pores through SC created by an electrical current.
Sonophoresis	Transport enhancement by heating and/or disordering SC by means of ultrasound.
Micro-needles	Microscopic needles, loaded with drug, punctures the SC thus increasing transdermal drug flux.
Chemical enhancers	Chemicals interacting with the structure of SC, leading to increased permeability of drug molecules through SC.
Carrier particles (e.g.	Drug enveloped in submicron particles with good SC

transfersomes, lipopearls)	permeability.
Jet injection	Rapidly expanding gas "shoots" drug particles through SC, leading to increased permeability of drug molecules.
Laser microporation	Laser light punctures SC, leading to increased permeability of drug molecules.
Tape stripping	Adhesive tape strips off SC, leading to increased permeability of drug molecules.
Suction ablation	Suction device strips off SC, leading to increased permeability of drug molecules.
Metabolic inhibitors	Chemicals that slows the reparative processes of the skin. Damaged SC more permeable to drug than undamaged SC.
Supersaturation	Maximizes the concentration gradient at the drug/SC interface thus optimizing transdermal diffusion of drug.
Occlusion	Transport enhancement through heating and/or disordering SC by means of an occlusive dressing.
Solvent drag	The transdermal flux of a highly permeable substance drags drug molecules along with it, thus increasing the transdermal transport rate of the drug.

The means of Table 2 are as such known in the art.

#### **The active ingredient**

According to the invention, the claimed device comprises nicotine in any form.

- 5 Nicotine is intended to include nicotine, 3-(1-methyl-2-pyrrolidinyl)-pyridine, with its base form, including synthetic nicotine as well as nicotine extracts from tobacco plants, or parts thereof, such as the genus *Nicotiana* alone or in combination.

- Nicotine in any form is selected from the group consisting of a nicotine salt, the free base form of nicotine, a nicotine derivative, such as a nicotine cation exchanger, a nicotine  
 10 inclusion complex or nicotine in any non-covalent binding; nicotine bound to zeolites; nicotine bound to cellulose or nicotine bound to starch microspheres; and mixtures thereof.

Numerous nicotine salts are known, and may be used, e g the salts presented in below Table 3.



**Table 3 Acids useful for nicotine salt formation**

Acid	Molar ratio* of acid:nicotine
Formic	2:1
Acetic	3:1
Propionic	3:1
Butyric	3:1
2-Methylbutyric	3:1
3-Methylbutyric	3:1
Valeric	3:1
Lauric	3:1
Palmitic	3:1
Tartaric	2:1
Citric	2:1
Malic	2:1
Oxalic	2:1
Benzoic	1:1
Gentisic	1:1
Gallic	1:1
Phenylacetic	3:1
Salicylic	1:1
Phthalic	1:1
Picric	2:1
Sulfosalicylic	1:1
Tannic	1:5
Pectic	1:3
Alginic	1:2
Hydrochloric	2:1
Chloroplatinic	1:1
Silicotungstic	1:1
Pyruvic	2:1
Glutamic	1:1
Aspartic	1:1

\* recommended upon production

The above-mentioned cation exchanger is preferably a polyacrylate.

The above-mentioned inclusion complex is preferably a complex with a cyclo-  
5 dextrin, such as  $\beta$ -cyclodextrin.

The above-mentioned nicotine salt is preferably a tartrate, hydrogen tartrate, citrate, maleate or hydrochloride.

The form of nicotine being provided through the basic administration may be another form of nicotine than the one being provided through the additional administration.

10 **Further additives**

Further additives may be added optionally to a device according to the present invention.

Optional additives preferably comprise one or more additives selected from the group consisting of stabilisers, enhancers and anti-irritants.

15 Stabilizers may be selected from the group consisting of antioxidants including vitamin E, i.e. tocopherole, ascorbic acid, sodium pyrosulfite, or butylated hydroxytoluene (BHT), butylated hydroxyanisole, edetic acid and edetate salts; and preservatives including citric acid, tartaric acid, lactic acid, malic acid, acetic acid, benzoic acid, and sorbic acid. Preferred embodiments comprise an antioxidant as the stabiliser, and even more preferably  
20 vitamin E and/or butylated hydroxytoluene (BHT).

Enhancers may be selected from the group consisting of

- alcohols, such as short chain alcohols, e.g. ethanol and the like, long chain fatty alcohols, e.g. lauryl alcohols, and the like, and polyalcohols, e.g. propylene glycol, glycerin and the like;
- 25 - amides, such as amides with long aliphatic chains, or aromatic amides like N,N-diethyl-m-toluamide;
- amino acids;
- azone and azone-like compounds;
- essential oils, i.e. essential oils or constituents thereof, such as l-carvone, l-menthone and  
30 the like;
- fatty acids and fatty acid esters, such as oleic acid, lauric acid and the like, further esters of fatty acids, such as isopropyl myristate, and various esters of lauric acid and of oleic acid and the like;

- macrocyclic compounds, such as cyclopentadecanone and cyclodextrins;
  - phospholipid and phosphate compounds, such as phospholipids;
  - 2-pyrrolidone compounds; and
  - miscellaneous compounds, like sulphoxides, such as dimethyl sulphoxides, and fatty acid
- 5 ethers, such as Laureth-9 and polyoxylaurylether.

Combinations of enhancers from different groups may prove useful and efficient.

An example of a useful anti-irritant is vitamin E.

### Examples

The below examples are illustrative and non-limiting. The numbers within brackets  
10 refer to the corresponding numbers in the figures.

Example 1, being schematically illustrated in Figure 1.

Basic administration from matrix part and additional administration from iontophoretic part.

A device in the format of a transdermal patch consisting of two different nicotine  
15 delivery systems:

One system where the transdermal dose of nicotine is delivered from a polymeric matrix compartment (11). The mechanism for transdermal nicotine delivery for this system is passive diffusion along a concentration gradient. The rate of delivery is governed by the properties of the matrix polymers and the concentration of nicotine loaded into the matrix.

20 The nicotine in the matrix is in its neutral, base form.

One system where the transdermal dose of nicotine is delivered from a compartment where the mechanism of nicotine transport is iontophoresis, i.e. the driving force is supplied by an electric current (12, 13). In this system positively charged nicotine is loaded in the electrode-fitted (anode) drug compartment (12). The system is completed by a  
25 second electrode-fitted (cathode) compartment (13) where negatively charged counter-ions, preferably chloride ions but also other biocompatible negatively charged ions may be used, are loaded. Electrodes (14) are preferably of the Ag/AgCl type. A disposable battery (14), capable of outputting a current of up to 0.5 mA/cm<sup>2</sup> of drug compartment area in contact with the skin, is connected to the electrodes. When the iontophoretic system is activated,  
30 the skin tissue at the application site completes the electrical circuit. The rate of nicotine delivery for this system is governed by the size of the electrical current between the electrodes (14).

The two above systems are placed side-by-side in a thin patch-like device 20-50 cm<sup>2</sup> in size. The device is fastened at the application site by means of an adhesive layer covering the bottom of the device. The device is backed by a flexible non-woven material, which provides structural support. Directly below the non-woven material is a thin  
5 aluminum layer, acting as a barrier to nicotine diffusion through the backing material of the device. The device is also fitted with an activation button (15) to initiate the driving electrical current of the iontophoretic system. The passive diffusion system provides a basic dose of nicotine. The user may activate the iontophoretic system by pressing the activation button (15), and thus release an additional dose of nicotine. Deactivation of the  
10 iontophoretic system is by a timer function. Alternatively, the user may at any time deactivate the additional administration of nicotine by pressing the activation button (15) a second time.

Example 2, being schematically illustrated in Figure 2.

Basic administration from reservoir part and additional administration from micro-  
15 needle part.

A device in the format of a transdermal patch consisting of two different nicotine delivery systems:

One system where the transdermal dose of nicotine is delivered from a reservoir compartment, through a rate-controlling membrane (21). The mechanism for transdermal  
20 nicotine delivery for this system is passive diffusion along a concentration gradient. The rate of delivery is governed by the properties of the rate-controlling membrane and the concentration of nicotine loaded into the compartment. The nicotine in the matrix is in its neutral, base form.

One system where the transdermal dose of nicotine is delivered from a reservoir  
25 compartment lined on one side with micro-needles with the function of being able to puncture the stratum corneum of the skin, thus increasing the transdermal delivery rate of nicotine (22). The micro-needles are suspended a short distance from the skin surface and the user may activate the system by pressing on the backing of the patch to bring the micro-needles in contact with the skin. The rate of delivery is governed by the properties of the  
30 micro-needles and the concentration of nicotine loaded into the compartment. The nicotine in the micro-needle reservoir compartment is in its neutral, base form.

The two above systems are placed side-by-side in a thin patch-like device 20-50 cm<sup>2</sup> in size. The device is backed by a flexible non-woven material, which provides

structural support. Directly below the non-woven material is a thin aluminum layer, acting as a barrier to nicotine diffusion through the backing material of the device. The device is fastened at the application site by means of an adhesive layer covering the bottom of the device. The immediate area surrounding the micro-needle part of the device consists of a semi-rigid flexing polymer (23) that will allow the micro-needles to flex in and out of contact with the stratum corneum (24) dictated by the user pressing on the backing of the device, directly behind the micro-needles. The passive diffusion system provides a basic dose of nicotine. The user may activate an additional dose of nicotine by pressing on the device backing so that the micro-needles puncture the stratum corneum (24) of the skin and channel nicotine through the stratum corneum (24) to the underlying tissue.

Example 3, being schematically illustrated in Figure 3.

Basic administration from matrix part and additional administration from ultrasonic part.

A device in the format of a transdermal patch consisting of two different nicotine delivery systems:

One system where the transdermal dose of nicotine is delivered from a polymeric matrix compartment (31). The mechanism for transdermal nicotine delivery for this system is passive diffusion along a concentration gradient. The rate of delivery is governed by the properties of the matrix polymers and the concentration of nicotine loaded into the matrix.

The nicotine in the matrix is in its neutral, base form.

One system where the transdermal dose of nicotine is delivered from a polymeric matrix compartment (32) where the mechanism of nicotine transport is sonophoresis, i.e. an ultrasonic device (33) causes heating of the skin and a reversible disordering of the structure of the stratum corneum. The rate of nicotine delivery for this system is governed by the intensity of the ultrasonic vibrations. The nicotine in the matrix is in its neutral, base form.

The two above systems are placed side-by-side in a thin patch-like device 20-50 cm<sup>2</sup> in size. The device is fastened at the application site by means of an adhesive layer covering the bottom of the device. The device is also fitted with an activation button (34) to initiate the ultrasonic vibrations. The passive diffusion system provides a basic dose of nicotine. The user may activate the sonophoretic system by pressing the activation button (34), and thus release an additional dose of nicotine. Deactivation of the sonophoretic

system is by a timer function. Alternatively, the user may at any time deactivate the additional administration of nicotine by pressing the activation button (34) a second time.

Example 4, being schematically illustrated in Figure 4.

Basic administration from matrix part sharing space with iontophoretic part providing additional administration.

A device in the format of a transdermal patch consisting of two different nicotine delivery systems:

One system where the transdermal dose of nicotine is delivered from a compartment where the mechanism of nicotine transport is iontophoresis, i.e. the driving force is supplied by an electric current. In this system positively charged nicotine is loaded in the electrode-fitted (anode) drug compartment (41). The system is completed by a second electrode-fitted (cathode) compartment (42) where negatively charged counter-ions are loaded. This compartment also contains the neutral base nicotine of the passive diffusion system detailed below. A battery (43) supplies the needed electrical power. The rate of nicotine delivery for this system is governed by the size of the electrical current between the electrodes.

One system where the transdermal dose of nicotine is delivered from a polymeric matrix compartment (42). This compartment contains both nicotine in its neutral, base form and the negatively charged counter-ions needed for the iontophoretic system. The mechanism for transdermal nicotine delivery for this system is passive diffusion along a concentration gradient. The rate of nicotine delivery is governed by the properties of the matrix polymers and the concentration of nicotine loaded into the matrix.

The two above systems are fitted in a thin patch-like device 20-50 cm<sup>2</sup> in size. The device is fastened at the application site by means of an adhesive layer covering the bottom of the device. The device is backed by a flexible non-woven material, which provides structural support. Directly below the non-woven material is a thin aluminum layer, acting as a barrier to nicotine diffusion through the backing material of the device. The device is also fitted with an activation button (44) to initiate the driving electrical current of the iontophoretic system. The passive diffusion part, located in the iontophoretic cathode compartment (42), provides a basic dose of nicotine. The user may activate the iontophoretic system by pressing the activation button (44), and thus release an additional dose of positively charged nicotine from the iontophoretic anode compartment (41). Deactivation of the iontophoretic system is by a timer function. Alternatively, the user may at any time deac-

tivate the additional administration of nicotine by pressing the activation button (44) a second time.

Example 5, being schematically illustrated in Figure 5.

Basic administration from reservoir part and additional administration from iontophoretic part, where the two parts may be individually applied to the skin.

A device in the format of a transdermal patch consisting of two different nicotine delivery systems:

One system where the transdermal dose of nicotine is delivered from a reservoir compartment, through a rate-controlling membrane (51). The mechanism for transdermal nicotine delivery for this system is passive diffusion along a concentration gradient. The rate of delivery is governed by the properties of the rate-controlling membrane and the concentration of nicotine loaded into the compartment. The nicotine in the matrix is in its neutral, base form.

One system where the transdermal dose of nicotine is delivered from a compartment where the mechanism of nicotine transport is iontophoresis, i.e. the driving force is supplied by an electric current. In this system positively charged nicotine is loaded in an electrode-fitted drug compartment (52). The system is completed by a second electrode-fitted compartment where negatively charged counter-ions are loaded (53). A battery (54) supplies the needed electrical power. The rate of nicotine delivery for this system is governed by the size of the electrical current between the electrodes.

The two above systems are placed side-by-side in a thin patch-like device 20-50 cm<sup>2</sup> in size. The device is fastened at the application site by means of an adhesive layer covering the bottom of the device. The device is backed by a flexible non-woven material, which provides structural support. Directly below the non-woven material is a thin aluminum layer, acting as a barrier to nicotine diffusion through the backing material of the device. The two systems are separated by a perforation (55) in the device, making it possible to tear off one system from the other for individual placement on the body of the two parts. The iontophoretic part of the device is also fitted with an activation button (56) to initiate the driving electrical current of the iontophoretic system. The passive diffusion system provides a basic dose of nicotine. The user may activate the iontophoretic system by pressing the activation button (56), and thus release an additional dose of nicotine.

Deactivation of the iontophoretic system is by a timer function. Alternatively, the user may

at any time deactivate the additional administration of nicotine by pressing the activation button (56) a second time.

Example 6, being schematically illustrated in Figure 6.

Basic administration from matrix part and additional, multilevel administration

5 from iontophoretic part.

A device in the format of a transdermal patch consisting of two different nicotine delivery systems:

One system where the transdermal dose of nicotine is delivered from a polymeric matrix compartment (61). The mechanism for transdermal nicotine delivery for this system is passive diffusion along a concentration gradient. The rate of delivery is governed by the properties of the matrix polymers and the concentration of nicotine loaded into the matrix. The nicotine in the matrix is in its neutral, base form.

One system where the transdermal dose of nicotine is delivered from a compartment where the mechanism of nicotine transport is iontophoresis, i.e. the driving force is supplied by an electric current. In this system positively charged nicotine is loaded in the electrode-fitted (anode) drug compartment (62). The system is completed by a second electrode-fitted (cathode) compartment (63) where negatively charged counter-ions are loaded. A battery (64) supplies the needed electrical power. The rate of nicotine delivery for this system is governed by the size of the electrical current between the electrodes.

The two above systems are placed side-by-side in a thin patch-like device 20-50 cm<sup>2</sup> in size. The device is fastened at the application site by means of an adhesive layer covering the bottom of the device. The device is backed by a flexible non-woven material, which provides structural support. Directly below the non-woven material is a thin aluminum layer, acting as a barrier to nicotine diffusion through the backing material of the device. The passive diffusion system provides a basic dose of nicotine. The device is also fitted with a set of activation buttons (65, 66, 67) to initiate the driving electrical current of the iontophoretic system. The user may activate the iontophoretic system by pressing one of the activation buttons (65, 66, 67), and thus release an additional dose of nicotine. The amount of nicotine of the additional dose ranges from low to high, depending on which button is pressed by the user. Each button corresponds to a pre-set dose level. Deactivation of the iontophoretic system is by a timer function. Alternatively, the user may at any time



deactivate the additional administration of nicotine by pressing the same activation button a second time.

**Further embodiments**

Other combinations of herein disclosed means for obtaining the basic administration and the additional administration respectively than those disclosed in the Examples are readily envisagable and useful.

The present device should preferably be occlusive.

The present device may deliver nicotine during a predefined period of time, preferably 12, 16, 24 or 48 hours.

10       The at least one part providing for basic transdermal administration and the at least one part providing for additional and user activatable transdermal administration may be combined in different ways. For example may said parts have at least one feature in common, e g a common adhesive layer and/or a common drug reservoir. Said parts may also be combined so that they have no features in common.

## CLAIMS

1. Device for transdermal administration of nicotine in any form, characterized in that it comprises at least one first part providing for basic administration of nicotine in any form and at least one second part providing for additional administration of  
5 nicotine in any form, the at least one second part being activatable by the user.

2. Device for transdermal administration according to claim 1, characterized in that the at least one first part providing for basic administration is/are (a) transdermal patch(es), preferably of the reservoir type, the matrix type, the drug-in-adhesive type and/or the multi-laminate type, preferably of the drug-in-adhesive type or the reservoir  
10 type or combinations of these two types.

3. Device for transdermal administration according to any preceding claim, characterized in that the at least one second part providing for additional administration comprise(s) means for iontophoretic delivery, sonophoresis, jet injection and/or micro-needles.

15 4. Device for transdermal administration according to claim 3, characterized in that the at least one second part providing for additional administration comprise(s) means for iontophoretic delivery.

5. Device for transdermal administration according to any preceding claim, characterized in that the at least one first part and the at least one second part have  
20 at least one feature in common.

6. Device for transdermal administration according to any of claims 1 - 5, characterized in that the at least one first part and the at least one second part are detachable from one another and/or may be individually applied.

7. Device for transdermal administration according to any preceding claim,  
25 characterized in that the form of nicotine is selected from nicotine free base, a nicotine salt, such as a tartrate, hydrogen tartrate, citrate, maleate or hydrochloride, a nicotine inclusion complex, such as a complex with a cyclodextrin, a nicotine cation exchanger, such as nicotine with polyacrylate or nicotine in any non-covalent binding, nicotine bound to zeolites, nicotine bound to cellulose or nicotine bound to starch  
30 microspheres, and mixtures thereof.

8. Device for transdermal administration according to claim 7, characterized in that the form of nicotine is nicotine free base.

9. Device for transdermal administration according to claim 7 or 8, characterized in that the least one part providing for basic administration of nicotine is for delivery of nicotine in another form than the at least one part providing for additional administration of nicotine
- 5 10. Device for transdermal administration according to anyone of the preceding claims, characterized in that it delivers nicotine during a predefined period of time, preferably 12, 16, 24 or 48 hours.
11. Device according to anyone of the preceding claims, characterized in that it further comprises one or more stabilisers, preferably selected from the group consisting of antioxidants including vitamin E, i.e. tocopherole, ascorbic acid, sodium pyrosul-  
10 fite, butylated hydroxytoluene (BHT), butylated hydroxyanisole, edetic acid and edetate salts, and preservatives including citric acid, tartaric acid, lactic acid, malic acid, acetic acid, benzoic acid, and sorbic acid, preferably vitamin E and/or butylated hydroxytoluene (BHT); and/or
- 15 that it further comprises one or more substances enhancing transdermal penetration, preferably a compound selected from the group consisting of
- alcohols, such as short chain alcohols, e.g. ethanol and the like, long chain fatty alcohols, e.g. lauryl alcohols, and the like, and polyalcohols, e.g. propylene glycol, glycerin;
  - amides, such as amides with long aliphatic chains, or aromatic amides like N,N-diethyl-  
20 m-toluamide;
  - amino acids;
  - azone and azone-like compounds;
  - essential oils, i.e. essential oils or constituents thereof, such as l-carvone, l-menthone and the like;
  - 25 - fatty acids and fatty acid esters, such as oleic acid, lauric acid and the like, further esters of fatty acids, such as isopropyl myristate, and various esters of lauric acid and of oleic acid;
  - macrocyclic compounds, such as cyclopentadecanone and cyclodextrins;
  - phospholipid and phosphate compounds, such as phospholipids;
  - 30 - 2-pyrrolidone compounds; and
  - miscellaneous compounds, like sulfoxides, such as dimethyl sulfoxides, and fatty acid ethers, such as Laureth-9 and polyoxylaurylether; and/or

that it further comprises one or more substances reducing irritant reactions, preferably vitamin E.


12. Device according to anyone of the preceding claims, characterized in that it is occlusive.

5 13. Use of nicotine for the manufacture of a device for aiding in smoking cessation, in temporary smoking abstinence and/or in reducing the urge to smoke or to otherwise use tobacco containing material, and/or for treating conditions suitable for treatment with nicotine, such conditions being selected from the group consisting of Alzheimer's disease, Crohn's disease, Parkinson's disease, Tourette's syndrome, ulcerous colitis and post-  
10 smoking-cessation weight control, such a device being according to anyone of claims 1 – 12.


14. Method for aiding in smoking cessation, in temporary smoking abstinence and/or in reducing the urge to smoke or to otherwise use tobacco containing material, and/or for treating conditions suitable for treatment with nicotine, such conditions being  
15 selected from the group consisting of Alzheimer's disease, Crohn's disease, Parkinson's disease, Tourette's syndrome, ulcerous colitis and post-smoking-cessation weight control, by transdermal administration of nicotine with a device according to anyone of claims 1 – 12.

15. Method for aiding in smoking cessation, in temporary smoking abstinence  
20 and/or in reducing the urge to smoke or to otherwise use tobacco containing material, and/or for treating conditions suitable for treatment with nicotine, such conditions being selected from the group consisting of Alzheimer's disease, Crohn's disease, Parkinson's disease, Tourette's syndrome, ulcerous colitis and post-smoking-cessation weight control, by transdermal administration of nicotine with a device according to anyone of claims 1 –  
25 12 in combination with means selected from mouth sprays, nasal sprays, transdermal patches, inhaling devices, lozenges, tablets and from parenteral methods, subcutaneous methods, intravenous methods, rectal methods, vaginal methods and transmucousal methods, including use of tobacco.


**Figure 1:**  
Iontophoresis + conventional patch




**Figure 2:**  
Microneedle array + conventional patch



**Figure 3:**  
Sonophoresis + conventional patch




**Figure 4:**  
Iontophoresis + drug diffusion from counter ion compartment






**Figure 5:**  
Iontophoresis + conventional patch "tear-off" system



**Figure 6:**  
Multilevel iontophoresis



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
29 September 2005 (29.09.2005)

PCT

(10) International Publication Number  
**WO 2005/089728 A3**

(51) International Patent Classification:  
A61K 9/70 (2006.01) A61K 9/00 (2006.01)  
A61K 31/465 (2006.01)

(21) International Application Number:  
PCT/IB2005/000673

(22) International Filing Date: 10 March 2005 (10.03.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0400685-4 19 March 2004 (19.03.2004) SE  
60/558,874 2 April 2004 (02.04.2004) US

(71) Applicant (for all designated States except US): **PFIZER HEALTH AB** [SE/SE]; S-112 87 Stockholm (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LINDELL, Eva, Anette, Katarina** [SE/SE]; Pfizer Health AB, Norrbroplatsen 2, S-251 09, Helsingborg (SE). **NICKLASSON, Per, Fredrik** [SE/SE]; Pfizer Health AB, Norrbroplatsen 2, S-251 09, Helsingborg (SE). **THYRESSON, Maarit, Kristina** [FI/SE]; Pfizer Health AB, Norrbroplatsen 2, S-251 09, Helsingborg (SE).

(74) Agents: **WOOD, David, J.** et al.; Pfizer Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:  
11 May 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 2005/089728 A3

(54) Title: MEANS FOR TRANSDERMAL ADMINISTRATION OF NICOTINE

(57) Abstract: Devices for transdermal administration of nicotine, which provide for basic as well as additional user activatable administration of nicotine, as well as use of such devices.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/IB2005/000673

A. CLASSIFICATION OF SUBJECT MATTER A61K9/70 A61K31/465 A61K9/00		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, EMBASE, BIOSIS		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 415 629 A (HENLEY ET AL) 16 May 1995 (1995-05-16) column 3, lines 40-58 column 4, line 36 - column 5, line 15 column 7, line 40 - column 8, last line ; claims 1,5,9,12	1-15
X	US 2001/033858 A1 (ZHANG JIE) 25 October 2001 (2001-10-25) cited in the application paragraph '0013'; claims 1,4,10,23; example 2	1,2, 5-10,12
Y		3,4, 13-15
----- -/-		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : 'A' document defining the general state of the art which is not considered to be of particular relevance 'E' earlier document but published on or after the international filing date 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) 'O' document referring to an oral disclosure, use, exhibition or other means 'P' document published prior to the international filing date but later than the priority date claimed 'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention 'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. 'A' document member of the same patent family		
Date of the actual completion of the international search 9 February 2006		Date of mailing of the international search report 17/02/2006
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax (+31-70) 340-3016		Authorized officer Marttin, E

# INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/IB2005/000673

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96/00111 A (CYGNUS THERAPEUTIC SYSTEMS) 4 January 1996 (1996-01-04) page 4, lines 4-26 page 5, lines 1-25 page 8, lines 18-30	1-12
Y	page 10, line 5 page 10, line 24 - page 11, line 2; claims 1,3,5,6,12	3,4, 13-15
X	US 5 505 957 A (D'ANGELO ET AL) 9 April 1996 (1996-04-09) column 2, lines 41-58	1,2,5-12
Y	column 3, lines 4-9,24-29 column 3, line 61 column 4, lines 22-34 column 8, lines 26-31; claims 1,2	3,4, 13-15
Y	US 5 721 257 A (BAKER ET AL) 24 February 1998 (1998-02-24) cited in the application column 4, line 37 - column 5, line 42 column 25, lines 47-62	13-15

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/IB2005/000673

### Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 14-15 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/IB2005/000673

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5415629	A	16-05-1995	US 5538503 A	23-07-1996
US 2001033858	A1	25-10-2001	EP 1280485 A1	05-02-2003
			JP 2003524652 T	19-08-2003
			WO 0164149 A1	07-09-2001
WO 9600111	A	04-01-1996	AU 2947795 A	19-01-1996
			CA 2194010 A1	04-01-1996
			EP 0766579 A1	09-04-1997
			JP 10511008 T	27-10-1998
US 5505957	A	09-04-1996	US 5405614 A	11-04-1995
US 5721257	A	24-02-1998	NONE	

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**